Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Academic Performance in Asian Children with ADHD
NCT00471354Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Primary endpoint: Correlation Between Change From Baseline and 24 Week Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent:Investigator-Administered and Scored Total Score and School Grade… Started Apr 2007; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00471354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471354.